SARS-CoV-2-IN-30 disodium
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1006.96 |
| Molecular Formula | C60H50Na2O8P2 |
| SMILES | CCC(C=C1)=CC=C1COP(OC(C2=C3C4C5=CC(C6CC7C8=C6C=CC=C8)=C7C=C5C2C4)=C(C9C%10=C(C%11C9)C=C%12C(C%13C%14=C(C%12C%13)C=CC=C%14)=C%10)C%11=C3OP(OCC%15=CC=C(C=C%15)CC)(O[Na])=O)(O[Na])=O |
Summary
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC 50 s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC 50 value of 6.9 μM [1] .
IC50 & Target
IC50: 6.9 μM (viral liposome, SARS-CoV-2) [1]
In Vitro
SARS-CoV-2-IN-30 (CP025) disodium inhibits SARS-CoV-2 (IC
50
=6.9 μM) with few cytotoxicity (Caco2 cells, CC
50
=106.1 μM)
[1]
.
SARS-CoV-2-IN-30 disodium (0-15 μM; 2 h) inactivate SARS-CoV-2, shows inhibition against infection with an IC
50
value of 0.6 μM
[1]
.
SARS-CoV-2-IN-30 disodium suppresses varies enveloped viruses activity with IC
50
s of 6.1 μM (respiratory syncytial virus, RSV), 3.2 μM (influenza A virus, IAV), 7.0 μM (measles virus, MeV), 1.1 μM (herpes simplex viruses, HSV-1), respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Caco2 cells exposed with SARS-CoV-2 (2 h, 37 ℃) |
| Concentration: | 0, 0.23, 0.93, 3.75, 15 μM |
| Incubation Time: | 2 hours; determined infection rates on day 2 |
| Result: | Inhibited SARS-CoV-2 infection activity to Caco2 cells. |
In Vivo
SARS-CoV-2-IN-30 (CP025) disodium (150 μM, 50 μL; intranasal route; for 2-5 d) shows antiviral activity in vivo against respiratory syncytial virus (RSV) and SARS-CoV-2 in BALB/cJ mice or K18-hACE2 mice, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice [1] |
| Dosage: | 150 μM, 50 μL |
| Administration: | Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2 |
| Result: |
Reduced viral load in the lungs of SARS-CoV-2-infected mice.
Completely abolished SARS-CoV-2 infection of all tested mice without changing body weight of mice. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.